Top of page

RADAR: A phase 3 trial of an antibody treatment called brentuximab vedotin in people with early stage Hodgkin lymphoma

This trial is testing brentuximab vedotin, combined with chemotherapy, in people with stage 1A or 2A Hodgkin lymphoma who haven’t had treatment before.


Trial aim and background

The aim of this trial is to find out if brentuximab vedotin, combined with chemotherapy, is more effective than standard treatment for people with early Hodgkin lymphoma.

People who take part in this trial are randomly allocated to one of two treatment groups:

  • People in group 1 have brentuximab vedotin combined with three chemotherapy drugs: doxorubicin, vinblastine and dacarbazine.
  • People in group 2 have four chemotherapy drugs: doxorubicin, bleomycin, vinblastine and dacarbazine.

Brentuximab vedotin is an antibody-drug conjugate: an antibody joined to a strong anti-cancer drug. The antibody sticks to a protein called CD30 on lymphoma cells and carries the drug directly to them. It is already available to treat some types of lymphoma that have come back or not responded after previous treatment, including Hodgkin lymphoma.

Doxorubicin, bleomycin, vinblastine and dacarbazine are all chemotherapy drugs.

At the end of the first cycle, everybody in the trial is offered a PET/CT scan

At the end of the second cycle, everybody in the trial has a PET/CT scan to find out how well they have responded to treatment.


Who can enter

Patients aged between 16 and 69 with stage 1A or 2A classical Hodgkin lymphoma affecting the upper part of their body who have not had any previous treatment may be eligible for this trial. 


Locations

Recruitment is taking place in the following UK locations:

  • Aberdeen Royal Infirmary, Aberdeen, United Kingdom, AB25 2ZN
  • Glan Clwyd Hospital, Bodelwyddan
  • Bristol Haematology and Oncology Centre, Bristol
  • University Hospital of Wales,  Cardiff & Vale University Local Health Board
  • Beatson West of Scotland Cancer Centre, Glasgow
  • Castle Hill Hospital, Hull
  • University Hospitals of Leicester NHS Trust, Leicester
  • St Bartholomew's Hospital, London
  • University College London Hospitals NHS Foundation Trust (UCLH), London
  • Christie Hospital, Manchester
  • Norfolk & Norwich University Hospital, Norwich
  • Nottingham University Hospitals NHST, Nottingham
  • Churchill Hospital, Oxford
  • Derriford Hospital, Plymouth
  • Torbay Hospital, Torquay
  • Royal Cornwall Hospital, Truro
  • Freeman Hospital, Newcastle

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT04685616

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.